UBS/CALL/IDORSIA/2.805/0.2/21.03.25 | Real-time Bid/Ask 06:19:22 2024-07-17 am EDT | ||
| 0.18 CHF / 0.2 CHF | +5.56% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
| Date | Price | Change |
|---|---|---|
| 24-07-15 | 0.18 | +5.88% |
Delayed Quote Swiss Exchange
Last update July 15, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | UBS |
| GPUBSU | |
| ISIN | CH1355587101 |
| Date issued | 2024-06-03 |
| Strike | 2.805 CHF |
| Maturity | 2025-03-21 (248 Days) |
| Parity | 5 : 1 |
| Emission price | 0.26 CHF |
| Emission volume | N/A |
| Settlement | physical |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.24 CHF |
|---|---|
| Lowest since issue | 0.17 CHF |
| Spread | 0.01 CHF |
| Spread % | 5.26% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
7
Last Close Price
2.276
CHF
Average target price
1.649
CHF
Spread / Average Target
-27.57%
- Stock Market
- Warrants
- GPUBSU Warrant
